Skip to main content
Back to Mizuho Capital

Mizuho Capital's Pharmaceutical Portfolio

Browse 6 Pharmaceutical companies funded by Mizuho Capital. See funding amounts, founder contacts, and investment details.

Pharmaceutical Companies
6
Total Funding in Pharmaceutical
$42.7M

Pharmaceutical Portfolio Companies (6)

Export
BiotechnologyGeneticsPharmaceutical

A-SEEDS is a biotech company that researches and develops regenerative medicines, especially for cancer patients.

Matsumoto, Japan
July 2025
$15.0M
Series A

Founder Contacts

30,000+ verified contacts

Health CareHealth DiagnosticsMedicalOncologyPharmaceutical

Linqmed is a pharmaceutical company that specializes in the research and development of radiopharmaceuticals for cancer treatment.

Chiba, Japan
May 2025
$2.0M
Series B

Founder Contacts

30,000+ verified contacts

BiotechnologyClinical TrialsMedicalPharmaceutical

Alivexis is a biotechnology company that engages in the research and development of custom medicine for the pharmaceutical industry.

Minato, Japan
March 2022
$20.4M
Series C

Founder Contacts

30,000+ verified contacts

Alternative MedicineBiotechnologyPharmaceuticalProduct Research

KAICO is a biotechnology company that provides hard-expressing proteins to develop drugs with a silkworm-baculovirus expression system.

Nishiku, Japan
April 2025
$3.8M
Series B

Founder Contacts

30,000+ verified contacts

AppsInformation TechnologyPharmaceuticalSoftware

Precal is an information technology company that develops applications for pharmacies, pharmacists, and dispensing clerks.

Tokyo, Japan
December 2024
$1.5M
Venture - Series Unknown

Founder Contacts

30,000+ verified contacts

Business Information SystemsCloud Data ServicesPharmaceutical

Veritas In Silico is a research and sales of pharmaceuticals firm that offers drug discovery platform technology with scientific evidences.

Tokyo, Japan
December 2021
Series C

Founder Contacts

30,000+ verified contacts

Explore Mizuho Capital's Full Portfolio

View all companies funded by Mizuho Capital across every industry and funding stage.

View Full Mizuho Capital Portfolio